Home / Events / HTA Vision—Implications Beyond the Rating


HTA Vision—Implications Beyond the Rating

Available On Demand

A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively discussion on the benefits of rapid access to cumulative, compounded learnings generated from in-depth analysis of global HTA recommendations, with presenters Mary Fletcher-Louis, Managing Director & Head of Trinity’s Value Center of Excellence and Andreia Ribeiro, Associate Principal.

Key Webinar Topics

  • Evidence and endpoint expectations for global HTA authorities
  • Population and subgroup strategies from products in the market today
  • Performance thresholds by disease areas to inform future new product expectations    
  • In- and cross-country decision trends and time to reimbursement to help predict agencies’ behavior and optimize evidence generation plans


Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.